Skip to main content
Caplight Logo









Hemab Therapeutics

Hemab Therapeutics

Private
—Healthcare & Life Scienceshttps://www.bitget.com/

Last Round

Series C

Oct 27, 2025

Total Funding Raised

$157M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

-

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Revenue Share

AI Layer

Non-AI

Keywords

bleeding disorder treatmentbispecific antibodyprophylactic therapeuticsclinical-stage biotechblood disordershematologythrombotic disorder treatmenthemostasisGlanzmann Thrombastheniaantibody therapyHemophilia A/Borphan drugFVIIarare pediatric diseaseVon Willebrand Disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hemab Therapeutics Comparables

Compare Hemab Therapeutics with similar companies based on industry and business-model similarity.

No public comparables are available for Hemab Therapeutics. Request access to learn about comparables coverage.

Request access

Hemab Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series COct 27, 2025

Hemab Therapeutics Investors

Notable investors and investment history

Hemab Therapeutics investors
InvestorRounds
Maj Invest Equity A/SSeries C
RA Capital ManagementSeries C
Avoro VenturesSeries C
Avoro CapitalSeries C
Deep Track CapitalSeries C
HealthCapSeries C
Novo HoldingsSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 27, 2025

    $157M round raised.

Hemab Therapeutics Filings

Explore SEC and related filing metadata, where available.

Hemab Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Hemab Therapeutics's valuation, stock price, and market status.

Is Hemab Therapeutics a public or private company?

Hemab Therapeutics is a private company.

What is the current stock price of Hemab Therapeutics?

Hemab Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Hemab Therapeutics worth (valuation)?

Valuation information for Hemab Therapeutics is not publicly available.

Can I buy Hemab Therapeutics stock?

Hemab Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Hemab Therapeutics's last funding round?

Hemab Therapeutics's most recent funding round was Series C on October 27, 2025.

Who are the main investors in Hemab Therapeutics?

Key investors in Hemab Therapeutics include Sofinnova Partners.

Will Hemab Therapeutics IPO soon?

No public IPO plans have been announced for Hemab Therapeutics.

How can I track Hemab Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Hemab Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

Headquarters—
Year FoundedN/A
Last FundingOct 27, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?